# EDGAR Filing Document

**Accession Number:** 0001873835
**File Stem:** 0001493152-26-002680
**Filing Date:** 2026-1
**Character Count:** 2683
**Document Hash:** bba54bb6dcf0d58aad21d2c99bce724e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-002680.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001493152-26-002680

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260116

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immix Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001873835
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 454869378
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 11400 WEST OLYMPIC BLVD.
- **STREET 2:** SUITE 200
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064
- **BUSINESS PHONE:** (888) 958-1084

**MAIL ADDRESS:**
- **STREET 1:** 10573 W. PICO BLVD.
- **STREET 2:** #58
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064

![](formcorresp_001.jpg)

January 16, 2026

 ****

***<u>VIA EDGAR</u>***

United States Securities

and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Mr. Tyler Howes

---

| | |
|:---|:---|
| **Re:** | **Immix Biopharma, Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **Filed January 9, 2026** <br>|
|  | **File No: 333-292665** |

---

Dear Mr. Howes,

Immix Biopharma, Inc. (the "**Registrant**") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-292665), be accelerated by the U.S. Securities and Exchange Commission (the "**Commission**") to become effective on **Tuesday, January 20, 2026**, at **5:00 p.m**., Eastern Time, or as soon as reasonably practicable thereafter.

The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

The Registrant hereby authorizes Leslie Marlow, Esq. and Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| IMMIX BIOPHARMA, INC. | IMMIX BIOPHARMA, INC. |
| By: | */s/ Gabriel Morris* |
| Name: | Gabriel Morris |
| Title: | Chief Financial Officer |

---

cc: Leslie Marlow, Esq., Blank Rome LLP <br> Melissa Murawsky, Esq., Blank Rome LLP